Tremfya Market Size & Growth Forecast 2027–2036, By Segments (Application, Distribution Channel), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Jump to Content
Market Size and Growth Outlook
Tremfya Market size was estimated at USD 4.08 billion in 2026 and is projected to grow at a 8.06% CAGR from 2027 to 2036, exceeding USD 8.86 billion by 2036. The industry revenue for 2027 is assessed at USD 4.36 billion.
Get more details on this report
Request Free Sample ReportTremfya Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 83.75% of the market in 2026, supported by established healthcare infrastructure, specialty care access, reimbursement systems, and awareness of advanced treatments for chronic inflammatory conditions.
- Improving diagnostic capabilities, expanding specialist healthcare services, and rising disease awareness are increasing access to advanced medicines, while growing healthcare expenditure supports broader adoption of innovative therapies.
Segment Momentum
- Plaque psoriasis accounted for 85.26% of market share in 2026, reflecting established use in moderate-to-severe disease management and sustained demand for therapies that support symptom control and quality of life.
- Psoriatic arthritis is the fastest-growing application segment, supported by greater disease recognition, earlier identification of joint involvement, and increasing interest in biologic therapies that address both joint and skin manifestations.
Market Expansion Drivers
- Increasing adoption of Tremfya for moderate-to-severe plaque psoriasis.
- Ongoing clinical trials expanding therapeutic indications.
- Market expansion in emerging economies with growing healthcare access.
Leading Market Participants
- Leading players in the tremfya market include Janssen (Johnson & Johnson) (USA), AbbVie (USA), Sun Pharma (India), Novartis (Switzerland), Eli Lilly (USA), Pfizer (USA), Merck & Co. (USA), Amgen (USA), UCB (Belgium), Bristol-Myers Squibb (USA).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 4.08 billion
- 2027 Estimated Market Size: USD 4.36 billion
- Projected Market Size: USD 8.86 billion by 2036
- Growth Forecast: 8.06% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Application (Plaque Psoriasis) | Distribution Channel (Hospital Pharmacies)
- Emerging Opportunity Segment: Application (Psoriatic Arthritis (PsA)) | Distribution Channel (Online Pharmacies)
Market Growth Drivers and Industry Trends
Increasing adoption of Tremfya for moderate-to-severe plaque psoriasis
Increasing adoption of tremfya for moderate-to-severe plaque psoriasis is being supported by the growing need for effective long-term management of chronic inflammatory skin conditions. Patients and healthcare professionals are increasingly seeking targeted therapies that can provide sustained disease control while addressing the recurring nature of plaque psoriasis. The treatment's targeted mechanism and established role in psoriasis management are contributing to its consideration within treatment pathways, particularly as healthcare providers increasingly emphasize therapies capable of improving skin clearance and supporting long-term disease management.
Ongoing clinical trials expanding therapeutic indications
Ongoing clinical research is supporting the potential expansion of tremfya into additional therapeutic applications by evaluating its efficacy and safety across broader patient populations and inflammatory conditions. Continued investigation can generate clinical evidence that informs treatment guidelines, physician awareness, and regulatory consideration for new indications. Moreover, research into additional disease areas can strengthen the therapy's role within immunology by demonstrating the applicability of targeted inflammatory pathway modulation beyond its established uses, potentially broadening patient access where appropriate approvals are obtained.
Market expansion in emerging economies with growing healthcare access
Growing healthcare access in emerging economies is creating opportunities for wider adoption of advanced therapies for chronic inflammatory diseases, including moderate-to-severe plaque psoriasis. Improvements in healthcare infrastructure, specialist availability, diagnostic capabilities, and patient awareness are increasing the identification and treatment of individuals who previously had limited access to specialized care. In addition, expanding insurance coverage and evolving reimbursement frameworks in developing healthcare systems can improve affordability and treatment accessibility, supporting greater utilization of biologic therapies as clinical awareness and treatment capacity continue to develop.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing adoption of Tremfya for moderate-to-severe plaque psoriasis | 3% | Short term (≤ 2 yrs) | North America; Europe; Spillover: Asia Pacific | Medium | Fast |
| Ongoing clinical trials expanding therapeutic indications | 2.5% | Medium term (2–5 yrs) | Europe; North America; Spillover: Asia Pacific | High | Moderate |
| Market expansion in emerging economies with growing healthcare access | 2% | Long term (5+ yrs) | Asia Pacific; Latin America; Spillover: MEA | Low | Moderate |
Explore Growth Opportunities
Request Free Sample ReportRegional Demand Dynamics
North America (Largest Region)
North America accounted for 83.75% share of the tremfya market in 2026, making it the largest regional market. The region’s strong position is backed by established healthcare infrastructure, high awareness of advanced treatment options, and broad access to specialty care for chronic inflammatory conditions. Increasing diagnosis and treatment of immune-mediated diseases are supporting demand for targeted therapies, while established reimbursement systems and specialist networks facilitate access to biologic treatments. Continued clinical research and growing emphasis on advanced disease management are further strengthening the regional market environment. Increasing patient and physician awareness of innovative therapeutic approaches is expected to sustain demand across the region.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to experience the fastest regional growth, supported by improving healthcare infrastructure, increasing disease awareness, and expanding access to advanced specialty medicines. Growing healthcare expenditure and improvements in diagnostic capabilities are enabling more patients to receive appropriate treatment for chronic inflammatory conditions. The expansion of specialist healthcare services and increasing availability of innovative therapies are further creating opportunities for market development. Greater awareness among healthcare professionals and patients, combined with improving treatment access and evolving healthcare systems, is expected to encourage broader adoption across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation HubiScaleNascentDeveloping Advanced | |||||
| Cost-Sensitive RegioniScaleLowMedium High | |||||
| Regulatory EnvironmentiScaleRestrictiveNeutral Supportive | |||||
| Demand DriversiScaleWeakModerate Strong | |||||
| Development StageiScaleEmergingDeveloping Developed | |||||
| Adoption RateiScaleLowMedium High | |||||
| New Entrants / StartupsiScaleSparseModerate Dense | |||||
| Macro IndicatorsiScaleWeakStable Strong |
Key Country Insights
United States 🇺🇸
Biologic Adoption HubThe U.S. market is centered on expanding Tremfya use across plaque psoriasis and psoriatic arthritis while supporting continued adoption through specialist prescribing and broader treatment pathways. Commercial priorities include maintaining differentiation within biologics and strengthening patient access as treatment options expand.
Germany 🇩🇪
Specialty Care IntegrationGermany’s Tremfya opportunity is closely tied to specialist-led biologic treatment and integration within established reimbursement pathways. Market priorities include demonstrating durable clinical value, supporting appropriate patient selection, and navigating payer and prescriber considerations across dermatology and rheumatology.
Japan 🇯🇵
Indication Expansion FocusJapan presents a market environment where Tremfya uptake depends on regulatory positioning across approved inflammatory conditions and specialist treatment practices. Priorities include expanding eligible patient use, communicating clinical differentiation, and aligning commercialization with Japan’s structured reimbursement and prescribing environment.
South Korea 🇰🇷
Specialty Biologic AccessSouth Korea’s Tremfya market is shaped by access to advanced biologic therapies through specialist channels, particularly in dermatology and immune-mediated diseases. Commercial priorities include reimbursement accessibility, physician familiarity, and evidence supporting treatment selection as biologic options continue to broaden.
France 🇫🇷
Reimbursement-Driven UptakeFrance’s Tremfya adoption is influenced by specialist prescribing and the country’s structured reimbursement environment for innovative therapies. Market priorities center on demonstrating therapeutic value, supporting appropriate biologic sequencing, and maintaining access across relevant dermatological and rheumatological indications.
Italy 🇮🇹
Specialist Treatment ExpansionItaly’s Tremfya market is shaped by specialist management of chronic inflammatory diseases and regional healthcare access considerations. Commercial priorities include strengthening physician adoption, supporting treatment continuity, and navigating reimbursement requirements for biologic therapies across dermatology and rheumatology.
Tremfya Market Share (%), by Application, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApplication Segment Analysis: Plaque Psoriasis (Largest Segment) vs Psoriatic Arthritis (PsA) (Fastest-Growing Segment)
The plaque psoriasis application segment accounted for the largest share of 85.26% in the tremfya market in 2026, reflecting the established role of the therapy in managing moderate-to-severe plaque psoriasis and the substantial treatment needs associated with this chronic inflammatory skin condition. Plaque psoriasis requires long-term disease management, creating sustained demand for effective therapies that can help control symptoms and improve patients' quality of life. Increasing recognition of biologic therapies as important treatment options for patients with more advanced disease is supporting utilization in this application. Treatment decisions are also influenced by factors such as disease severity, previous therapy response, tolerability, and the need for sustained symptom control. Continued diagnosis of plaque psoriasis, greater awareness of advanced treatment options, and ongoing management of patients requiring systemic therapies are expected to maintain the segment's prominent position.
The psoriatic arthritis (PsA) application segment is expected to grow at the fastest pace during the forecast period, supported by increasing recognition of psoriatic arthritis as a systemic inflammatory condition requiring effective long-term management of both joint and skin manifestations. Greater awareness among healthcare professionals of the connection between psoriasis and psoriatic arthritis can support earlier identification of patients with joint involvement and encourage timely treatment. The growing emphasis on therapies that can address multiple disease manifestations is also strengthening interest in biologic treatment options for patients with psoriatic arthritis. Improvements in disease recognition, expanding treatment pathways, and greater attention to preventing progression of joint symptoms are expected to support increasing adoption in this application. As diagnosis and management of psoriatic arthritis become more integrated with comprehensive care for patients with psoriasis, demand in this segment is expected to expand.
Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Online Pharmacies (Fastest-Growing Segment)
The hospital pharmacies segment accounted for the largest share of 52.74% in the tremfya market in 2026, supported by the specialized nature of biologic therapy distribution and the important role of healthcare providers in treatment initiation, monitoring, and patient management. Hospital pharmacies provide controlled medication handling and dispensing in an established clinical environment, facilitating coordination between prescribing specialists, pharmacists, and patients. Their integration with hospital-based dermatology and rheumatology services can support appropriate prescription management, treatment education, and follow-up for patients receiving long-term biologic therapy. Hospital pharmacies can also help maintain established procedures for medication storage, dispensing, and patient support, which are particularly relevant for specialty medicines. As healthcare providers continue to manage complex inflammatory diseases through specialized treatment pathways, hospital pharmacies are expected to remain an important distribution channel.
The online pharmacies segment is expected to grow at the fastest pace during the forecast period, driven by increasing adoption of digital healthcare services and consumer demand for convenient access to prescription medicines. Online pharmacy platforms can simplify prescription management, medication ordering, refill coordination, and home delivery, reducing the need for patients to make frequent trips to physical pharmacies where appropriate. Integration with digital healthcare services can also improve communication around prescriptions and support continuity of long-term treatment. As patients and healthcare providers increasingly use telemedicine, electronic prescriptions, and connected healthcare platforms, online pharmacies are gaining greater relevance in specialty medicine distribution. Growing consumer familiarity with digital purchasing and continued expansion of home-delivery healthcare services are expected to support increasing adoption of online pharmacy channels.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | Plaque Psoriasis, Psoriatic Arthritis (PsA), Others | Plaque Psoriasis | Psoriatic Arthritis (PsA) |
| Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies | Hospital Pharmacies | Online Pharmacies |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Competitive Landscape and Market Positioning
Analyst Perspective:
Tremfya's competitive position depends on the relationship between its IL-23-targeted mechanism, clinical outcomes, long-term treatment suitability, and patient access. Its efficacy and safety profile must be evaluated against alternative biologics within relevant approved indications, with response consistency and sustained disease management informing treatment decisions. Long-term safety evidence and immunogenicity findings also contribute to physician confidence, although meaningful comparisons require consideration of study populations, follow-up periods, and clinical outcomes. Expansion across additional approved autoimmune indications can broaden its role in specialist treatment pathways, but each indication brings distinct evidence requirements and competitive dynamics. Commercial uptake is further shaped by formulary placement, reimbursement restrictions, prior authorization, and patient support arrangements. Consequently, clinical differentiation alone does not determine market performance; access conditions and the therapy's practical fit within established treatment pathways remain influential.
Major players in the tremfya market:
- Janssen (Johnson & Johnson) (USA)
- AbbVie (USA)
- Sun Pharma (India)
- Novartis (Switzerland)
- Eli Lilly (USA)
- Pfizer (USA)
- Merck & Co. (USA)
- Amgen (USA)
- UCB (Belgium)
- Bristol-Myers Squibb (USA)
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Janssen (Johnson & Johnson) (USA) | |||||||
| AbbVie (USA) | |||||||
| Sun Pharma (India) | |||||||
| Novartis (Switzerland) | |||||||
| Eli Lilly (USA) | |||||||
| Pfizer (USA) | |||||||
| Merck & Co. (USA) | |||||||
| Amgen (USA) | |||||||
| UCB (Belgium) | |||||||
| Bristol-Myers Squibb (USA) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Johnson & Johnson | May 2026 | Johnson & Johnson received FDA approval to expand the label for Tremfya to treat adults with active psoriatic arthritis, backed by Phase 3b APEX study data demonstrating efficacy in slowing or preventing structural joint damage progression. |
| Johnson & Johnson | March 2025 | Johnson & Johnson secured FDA approval for Tremfya as the first interleukin-23 inhibitor offering both subcutaneous and intravenous delivery options for adults with moderate-to-severely active Crohn's disease. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Tremfya Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Treatment Line | First-Line Therapy, Second-Line Therapy, Later-Line Therapy |
| Prescriber Type | Dermatologists, Rheumatologists, Primary Care Physicians, Other Specialists |
| Patient Care Setting | Hospitals & Hospital Outpatient Departments, Specialty Clinics, Physician Offices, Ambulatory Care Centers |
Tremfya Market — Custom TOC
| Custom Chapter | Chapter Details |
|---|---|
| Patient Treatment Journey and Care Pathway Mapping |
|
| Biologic Switching Dynamics |
|
| Reimbursement and Access Environment |
|
Need a different cut of the data?
Request Custom ResearchFrequently Asked Questions
What is the overall size of the tremfya market?
What is the expected industry size of tremfya by 2036?
How is ongoing clinical research influencing the strategic growth potential of Tremfya?
How is expanding healthcare access supporting Tremfya adoption in emerging economies?
Why does plaque psoriasis dominate the Tremfya market?
What is driving growth in Tremfya use for psoriatic arthritis?
Why does North America account for the largest share of the Tremfya market?
How is Asia Pacific supporting future growth in the Tremfya market?
Which companies dominate the tremfya landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.
Delivery
Published
Available
Support
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook